Shots:
- Zydus Lifesciences has reported Tishtha, biosimilar version of Opdivo (Nivolumab), is now available in the India
- Tishtha will be available in 100 mg and 40 mg strengths
- Nivolumab is a mAb targeting PD-1 to enhance anti-tumor immune responses and is approved worldwide for cancers, including melanoma, mesothelioma, head and neck, and urothelial carcinoma
Ref: Zydus | Image: Zydus | Press Release
Related News: Shanghai Henlius Receives the US FDA IND Clearance for HLX18 (Biosimilar, Opdivo)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
